GlobeImmune, Inc.

Biopharmaceutical start-up companies – firms founded four years ago or less – raised fewer dollars during the third quarter than during the prior quarter despite Roivant Sciences GMBH 's massive $1

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal i

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Nov. 9-21. Deal Watc

Global Blood Therapeutics launched an initial public offering at $20 per share and its stock price more than doubled to $43.11 at the end of its first day of trading on Aug. 12, proving that investors